Fulcrum Therapeutics, Inc.

NasdaqGM:FULC 주식 보고서

시가총액: US$162.1m

Fulcrum Therapeutics 배당금 및 환매

배당금 기준 확인 0/6

Fulcrum Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-1.8%

환매 수익률

총 주주 수익률-1.8%
미래 배당 수익률0%
배당금 성장n/a
다음 배당금 지급일n/a
전 배당일n/a
주당 배당금n/a
지급 비율n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth

Nov 08
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth

Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Sep 13
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly

Sep 12

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Jul 12
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Feb 11
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Oct 28
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Jul 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13
Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Aug 11

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Jul 11

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Jul 05

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Jun 27

These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

May 10
These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Apr 09
Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Dec 09
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point

Sep 03

Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

Aug 12
Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Aug 11
News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 FULC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: FULC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.


시장 대비 배당 수익률

Fulcrum Therapeutics 시장 대비 배당 수익률
FULC 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트배당 수익률
회사 (FULC)n/a
시장 하위 25% (US)1.4%
시장 상위 25% (US)4.3%
업계 평균 (Pharmaceuticals)2.5%
애널리스트 예측 (FULC) (최대 3년)0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 FULC 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 FULC 의 배당 수익률을 평가할 수 없습니다.


주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 FULC 의 지급 비율을 계산하기에는 데이터가 부족합니다.


주주에 대한 현금 배당금

현금 흐름 범위: FULC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.


강력한 배당금 지급 기업 알아보기